Legend Biotech Corporation
LEGN
Hisse Senetlerindeki Sıralama
#4420
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Hisse Fiyatı
$19.00
Piyasa Değeri
$3.51B
Değişim (1 gün)
1.85%
Değişim (1 yıl)
-42.28%
Ülke
US
Ticaret Legend Biotech Corporation (LEGN)
Kategori
Healthcare
Legend Biotech Corporation (LEGN) için P/S oranı
October 2026 itibarıyla P/S oranı TTM: 2.77
Legend Biotech Corporation şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 2.77'dir. 2023 yılının sonunda şirketin P/S oranı 18.58 idi.
Legend Biotech Corporation için P/S oranı geçmişi 2017 - 2026 arası
Her yılın sonunda P/S oranı
| Yıl | P/S Oranı | Değiştir |
|---|---|---|
| 2026 (TTM) | 2.77 | -41.57% |
| 2024 | 4.74 | -74.47% |
| 2023 | 18.58 | -45.24% |
| 2022 | 33.93 | -7.19% |
| 2021 | 36.56 | 66.30% |
| 2020 | 21.98 | -48.45% |
| 2019 | 42.65 | 13.26% |
| 2018 | 37.65 | -63.62% |
| 2017 | 103.51 | 0.00% |
Benzer şirketler veya rakipler için P/S oranı
| Şirket | P/S Oranı | P/S Oranı Farkı | Ülke |
|---|---|---|---|
| 10.02 | 261.83% |
US
|
|
| 40.55 | 1,364.03% |
US
|
|
| 3.96 | 43.01% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 266.32% |
NL
|
